A carregar...
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue in the BTK kinase domain. BTK is a pivotal protein for B cell receptor signaling and tissue homing of CLL cells. Pr...
Na minha lista:
| Publicado no: | Blood Cancer J |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8085243/ https://ncbi.nlm.nih.gov/pubmed/33927183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00467-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|